MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer

Conflicting reports exist regarding the contribution of SNP309 in MDM2 to cancer risk. Recently, SNP285 was shown to act as an antagonist to SNP309 by overriding the effect of SNP309 on SP1‐mediated transcription. Moreover, SNP285 modified the relationship between SNP309 and risk of breast, ovarian and endometrial cancer. We assessed whether SNP285 confounded the effect of SNP309 in lung cancer in a cohort of 720 controls and 556 cases. Our cohort included both Caucasians and African Americans. Neither SNP309 nor SNP285 was associated with lung cancer risk or survival. In addition, removal of individuals who carried the variant C allele of SNP285 did not modify the association between SNP309 with either lung cancer risk or survival. Although an effect of SNP285 has been demonstrated in breast, ovarian and endometrial cancer, our findings do not support a role for this SNP in lung cancer and raise the possibility that the effect of SNP285 is restricted to cancers in women.

[1]  P. Lønning,et al.  SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. , 2012, European journal of cancer.

[2]  T. Fairley,et al.  Racial and regional disparities in lung cancer incidence , 2012, Cancer.

[3]  Hongbing Shen,et al.  MDM2 SNP309 contributes to non‐small cell lung cancer survival in Chinese , 2011, Molecular carcinogenesis.

[4]  P. Lønning,et al.  MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk , 2011, Oncotarget.

[5]  Dongxin Lin,et al.  The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. , 2011, Cancer cell.

[6]  G. Wahl,et al.  The p53 orchestra: Mdm2 and Mdmx set the tone. , 2010, Trends in cell biology.

[7]  K. Sabapathy,et al.  Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore , 2010, BMC Cancer.

[8]  A. Thompson,et al.  MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism , 2008, BMC Cancer.

[9]  K. Hemminki,et al.  MDM2 SNP309 and cancer risk: a combined analysis. , 2007, Carcinogenesis.

[10]  J. Klijn,et al.  MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling , 2007, Breast Cancer Research and Treatment.

[11]  D. Neuberg,et al.  MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Dong Sun Kim,et al.  Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer , 2007, Molecular carcinogenesis.

[13]  J. Park,et al.  MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. , 2006, Lung cancer.

[14]  E. Bowman,et al.  MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[15]  S. Zienolddiny,et al.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.

[16]  A. Levine,et al.  MDM2 SNP309 accelerates colorectal tumour formation in women , 2006, Journal of Medical Genetics.

[17]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[18]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[19]  Leah E. Mechanic,et al.  Exploring SNP‐SNP interactions and colon cancer risk using polymorphism interaction analysis , 2006, International journal of cancer.

[20]  Hongbing Shen,et al.  Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population , 2006, International journal of cancer.

[21]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[22]  Eva Enmark,et al.  Ligand-, Cell-, and Estrogen Receptor Subtype (α/β)-dependent Activation at GC-rich (Sp1) Promoter Elements* , 2000, The Journal of Biological Chemistry.

[23]  S. Ishiguro,et al.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. , 1997, British Journal of Cancer.

[24]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[25]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[26]  J. Gustafsson,et al.  Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. , 2000, The Journal of biological chemistry.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.